Man dies after quitting smoking triggers fatal reaction to his medication

A 29-year-old man from Worcester who suffered from paranoid schizophrenia has died after his decision to quit cigarettes turned his anti-psychotic medication fatally toxic.

Jack Burton, described as a "heavy smoker", passed away from clozapine toxicity roughly three days after giving up cigarettes during a holiday in North Yorkshire.

The tragedy has prompted a coroner to issue a prevention of future deaths report, warning no adequate guidance exists for medical practitioners on how to adjust clozapine dosages when patients cease smoking.

Burton had been taking the drug nightly under the supervision of his community psychiatrist.

He was prescribed a nightly dose of 525mg of clozapine, which was deemed the appropriate amount for someone who smoked heavily, as cigarettes are known to diminish the drug's efficacy.

TRENDING

Stories

Videos

Your Say

When he chose to stop smoking whilst holidaying in North Yorkshire, however, that same dosage became dangerously excessive. Without the counteracting effect of tobacco, clozapine levels in his bloodstream rose to toxic concentrations.

The inquest heard Burton died approximately three days after his last cigarette. His official cause of death was recorded as clozapine toxicity, the direct consequence of an abrupt cessation nobody had apparently anticipated or managed.

Worcestershire assistant coroner Deborah Lakin concluded Burton "should have informed his psychiatrist to reduce the amount of clozapine he was taking" before attempting to quit, noting that an excessive dose "could cause seizures".

His sudden death and the absence of clinical protocols on the matter compelled Ms Lakin to produce a prevention of future deaths report.

LATEST DEVELOPMENTS

• Sugar rationing in early childhood linked to 27% lower dementia risk
• Industrial chicken farming linked to spread of gut bug behind food poisoning
• Machine that keeps donated lungs outside the body approved for NHS use

She expressed concern further fatalities could follow unless clearer guidance is developed around clozapine prescribing and smoking cessation.

The report underscored, at present, there is simply no standardised framework available to doctors navigating this potentially lethal interaction between tobacco use and antipsychotic medication.

The inquest also revealed troubling inconsistencies in the medical evidence presented.

Ms Lakin noted "there were inconsistent accounts provided to me by two consultant psychiatrists about the relevance of reduction in smoking, rather than cessation of smoking, attributable to there being no guidance available to doctors on this issue".

It remained unclear throughout proceedings whether Burton had ever been properly advised about the risks associated with his medication and smoking.

Ms Lakin further observed no standardised practice exists for recording whether patients have been asked about side effects, meaning practitioners may keep no notes if no information is volunteered – leaving no trail of whether crucial questions were ever posed.

Our Standards: The GB News Editorial Charter